Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences will host a webcast fireside chat at a major healthcare investor conference with replay access for 90 days.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aura Biosciences (AURA) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026, featuring a fireside chat at 2:35 p.m. ET with CEO and President Natalie Holles.
A live webcast and a 90-day replay will be available on the company’s website under the Investors & Media, Events & Presentations section.
Details
News Market Reaction – AURA
On Sep 3, the first trading day after this news, AURA closed 1.73% below the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference:
- Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.
Fireside Chat at 2:35 p.m. ET
The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.
For more information, visit aurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.
Investor and Media Relations Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.